Skip to main content
Explore URMC

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Research Question:
Does the drug Darbe improve cognitive function in preterm infants?

Basic Study Information

Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo

Location: University of Rochester

Study Contact Information

Study Coordinator: Carl T D'Angio, MD
Phone: (505) 272-0180

Additional Study Details

Learn More About These Conditions

More information about Premature Birth

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search